Robert Tierney, MD
Rheumatology · St Louis Park, MNNPI 1992782882
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,883 of the $137,024 with a category attached, or 83.1%. 4 manufacturers reported payments, led by Amgen at 51.9% of the total. Reporting peaked in 2019 at $103,444 and has fallen 99.2% since, to $800 in 2024. Among rheumatology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $778.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$71K
- Bristol Myers Squibb$55K
- Sanofi$7K
- Regeneron Healthcare Solutions, Inc.$4K
What the payments were for
- Consulting fees$4,5183%
- Speaking & faculty fees$113,88383%
- Travel & lodging$14,65911%
- Food & beverage$3,9643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 86 | $71,050 |
| Bristol Myers Squibb | 69 | $55,426 |
| Sanofi | 9 | $7,031 |
| Regeneron Healthcare Solutions, Inc. | 12 | $3,516 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$137,024 in reported general payments places this provider in the 95th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 33 | $233,687 |
| Humira(Cf) PenAdalimumab | 14 | $96,792 |
| MethotrexateMethotrexate Sodium | 441 | $15,264 |
| Hydroxychloroquine Sulfate | 183 | $7,987 |
| Prednisone | 380 | $3,063 |
| Leflunomide | 47 | $2,379 |
| Celecoxib | 28 | $1,844 |
| Sulfasalazine | 27 | $1,228 |
| Mycophenolate Mofetil | 12 | $812 |
| Allopurinol | 51 | $744 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 41 | $483 |
| Pregabalin | 15 | $349 |
| Tramadol Hcl | 17 | $322 |
| Naproxen | 22 | $312 |
| Meloxicam | 48 | $189 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in St Louis Park
- Asim KhanMaple Grove$1.2M
- Parastoo FazeliMinneapolis$149K
- Ali SajjadMaplewood$87K
- Steven YtterbergRochester$87K
- Cornelia WeyandRochester$59K
- Eric MattesonRochester$51K
- Jeffrey WilsonEdina$49K
- John DavisRochester$32K
- David RidleyEagan$26K
- Ashima MakolRochester$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.